Short answer
Replimune Group, Inc. (REPL) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$83M
- −56.6% YoY · +4.1% QoQ
- EPS (diluted)
- −$0.90
- −34.3% YoY · +5.3% QoQ
Source: XBRL data from the Replimune Group, Inc. (REPL) Q3 2025 10-Q on SEC EDGAR. USD.
Replimune Group, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly highlighted tariff risk, triggered by threatened U.S. administration tariffs on pharmaceuticals and pharmaceutical ingredients without available exceptions
- Most material regulatory update, FDA CRL for RP1 plus nivolumab BLA in July 2025 followed by accepted resubmission in October 2025
- Clinical development risk, FDA may require larger Phase 3 or randomized controlled trials before RP1 approval
- Supply-chain risk, checkpoint combinations depend on BMS, Regeneron, and Roche supplying nivolumab, cemiplimab, atezolizumab, and bevacizumab
- Financial risk, continued substantial net losses and expected additional financing needs to complete trials and commercialization preparation
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Replimune Group, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.